La vendita allo scoperto per ANI Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di ANI Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

ANI Pharmaceuticals (NASDAQ:ANIP) Azioni, Report sulle vendite allo scoperto

ANI Pharmaceuticals

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Inc

Alnylam Pharmaceuticals&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) announced that it has submitted a Type II Variation to the&nbsp;European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM). Shares of the company gained 4.6% in response to the encouraging news.
Please note that Alnylam already markets vutrisiran in the EU under the brand name Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
The application seeking approval for vutrisiran to treat ATTR-CM is supported by positive&nbsp;results from ALNY&#39;s pivotal phase III HELIOS-B study, which met all primary and secondary endpoints across both the overall and monotherapy populations, each with statistical significance.
Year to date, shares of Alnylam have gained 57% against the industry&#39;s 1% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/81532.jpg?v=982164009" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
Per the data readout, vutrisiran reduced mortality and cardiovascular events while improving functional capacity (measured by the six-minute walk test), quality of life (using the Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (via New York Heart Association class) in ATTR-CM patients.
Additionally, the safety profile of vutrisiran in the HELIOS-B study was consistent with its known profile for treating hATTR amyloidosis with polyneuropathy in adults. In the late-stage study, the rates of adverse events, including those leading to discontinuation, were similar between the vutrisiran and placebo groups.
<h2>Amvuttra &ndash; The Key Growth Driver for Alnylam</h2>
Please note that Alnylam also markets Amvuttra, the company&#39;s lead drug, in the United States for the treatment of adult patients with polyneuropathy of&nbsp;hATTR amyloidosis. The drug&#39;s sales contribute significantly to ALNY&#39;s top line. Amvuttra generated sales worth $425.4 million in the first half of 2024, up 82% year over year on a reported basis. The encouraging uptake of the drug is driven by new patients starting treatment as well as patients switching from Onpattro. Onpattro is approved in the United States and EU to treat hATTR amyloidosis in adults.
We remind the investors that a supplemental new drug application for vutrisiran, seeking its label expansion to treat ATTR-CM is also currently under review in the United States. If the regulatory applications in the EU and the United States are approved, Alnylam believes that vutrisiran has the potential to become the new standard of care for the treatment of ATTR-CM. This will expand the eligible patient population for the drug driving substantial growth for the company in the future.
Other marketed products include Givlaari for acute hepatic porphyria and Oxlumo injection for subcutaneous use for the treatment of primary hyperoxaluria type 1 to lower urinary and plasma oxalate levels in pediatric and adult patients.
Alnylam also markets a fifth drug, Leqvio (inclisiran), in collaboration with Novartis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvs#NYSE">NVS</a>) to treat hypercholesterolemia in the EU. In the United States, it is approved to reduce low-density lipoprotein cholesterol (LDL-C) with two doses per year. Per the agreement, Alnylam has granted Novartis exclusive and worldwide rights to manufacture and commercialize RNAi therapeutics targeting PCSK9 for treating hypercholesterolemia and other human diseases, including Leqvio. Novartis has also received FDA approval to expand Leqvio&#39;s label to include earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy.
<div class="chart_embed">
<h3>Alnylam Pharmaceuticals, Inc. Price and Consensus</h3>
<img alt="Alnylam Pharmaceuticals, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/cd/1729169675.png" style="height:310px; width:600px" title="" />
Alnylam Pharmaceuticals, Inc. price-consensus-chart | Alnylam Pharmaceuticals, Inc. Quote
</div>
<h2>ALNY&#39;s Zacks Rank and Other Stocks to Consider</h2>
Alnylam currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are&nbsp;ANI Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>) and Amicus Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fold#NASDAQ">FOLD</a>). While ANIP sports a Zacks Rank #1 (Strong Buy), FOLD carries a Zacks Rank #2 at present.
In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.69 to $4.81. EPS estimates for 2025 have improved from $5.37 to $5.86, during the same period. Year to date, shares of ANIP have gained 8.2%.
ANI Pharmaceuticals&#39; earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Amicus&#39; 2024 EPS have remained constant at 20 cents. EPS estimates for 2025 have increased from 48 cents to 50 cents, during the same period. Year to date, shares of FOLD have lost 26%.
Amicus&#39; earnings beat estimates in three of the four trailing four quarters, missing the mark once, with the average surprise being 23.96%.
<a href="https://www.zacks.com/stock/news/2352442/alnylam-stock-up-on-cardiomyopathy-drug-regulatory-filing-in-the-eu?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2352442">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ALNY

ANIP

FOLD

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

MeiraGTx Holdings&#39; (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgtx#NASDAQ">MGTX</a>) clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson&#39;s disease (PD) met&nbsp;its primary study objective of safety&nbsp;and tolerability. The stock soared 14.9% in response to the news.
<h2>MGTX&#39;s PD Gene Therapy Candidate Betters Sham Treatment</h2>
The MGT-GAD-025 study of AAV-GAD for PD demonstrated significant and clinically meaningful improvements from baseline for key efficacy endpoints after 26 weeks of treatment.
Per the data readout, treatment with the candidate resulted in a statistically significant 18-point average improvement from baseline in the&nbsp;UPDRS Part 3 (motor examination) &quot;off&quot; medication score&nbsp;in the high-dose group at week 26. However, no significant change in the sham or low-dose groups was observed.
Additionally, MeiraGTx reported significant dose-dependent improvements from baseline in the disease-specific, patient-reported quality of life PDQ-39 score in both the high and low-dose groups with no significant change in the sham group at 26 weeks.
Year to date, shares of MeiraGTx have plunged 24.1% compared with the industry&#39;s 1.8% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4c/81354.jpg?v=599947683" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
The investigational gene therapy was also found to be generally safe and overall well-tolerated. No serious, AAV-GAD treatment-related adverse events were&nbsp;observed.
Per MGTX, PD is the second most common neurodegenerative disorder after Alzheimer&#39;s, affecting nearly one million people in the United States, with around 90,000 new cases diagnosed annually. Globally, more than 10 million people are living with PD. Initially, most patients respond well to dopamine replacement therapy, but over time, its effectiveness often diminishes and adverse side effects may arise, significantly impacting quality of life and daily functioning. This represents a high unmet medical need.
While the cause of PD remains unknown for most, a small percentage have a genetic basis. In all cases, PD involves disruptions in movement control circuits.
AAV-GAD has a novel mechanism of action that aims to correct the aberrant circuitry that results from the depletion of dopamine in the brain of idiopathic PD patients as the disease progresses. Using the company&#39;s proprietary delivery instrument, AAV-GAD is administered as a one-time infusion into the subthalamic nucleus, a key regulator of the circuits responsible for normal movement.
<h2>MGTX&#39;s Path Forward for AAV-GAD Following Upbeat Results</h2>
Based on the encouraging data readout from the MGT-GAD-025 study, MeiraGTx is currently gearing up to discuss these results with regulatory bodies in the United States, EU and Japan to potentially initiate a phase III study that will support the approval of this disease-modifying treatment globally.
Apart from AAV-GAD, the company has multiple other programs in clinical development, including the phase III Lumeos study for X-linked retinitis pigmentosa, phase I/II programs in achromatopsia and RPE65-deficiency, phase II study for radiation-induced xerostomia and a different mid-stage study for Sjogren&#39;s syndrome.
<div class="chart_embed">
<h2>MeiraGTx Holdings PLC Price and Consensus</h2>
<img alt="MeiraGTx Holdings PLC Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/28/1729082088.png" style="height:310px; width:600px" title="" />
MeiraGTx Holdings PLC price-consensus-chart | MeiraGTx Holdings PLC Quote
</div>
<h2>MGTX&#39;s Zacks Rank &amp; Stocks to Consider</h2>
MeiraGTx currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are&nbsp;ANI Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), Alnylam Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) and Amicus Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fold#NASDAQ">FOLD</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.69 to $4.81. EPS estimates for 2025 have improved from $5.37 to $5.86, during the same period. Year to date, shares of ANIP have gained 6.3%.
ANI Pharmaceuticals&#39; earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Alnylam&#39;s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per shares estimates for 2025 have narrowed from 34 cents to 26 cents, during the same period. Year to date, shares of ALNY have risen 50.1%.
Alnylam&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
In the past 60 days, estimates for Amicus&#39; 2024 EPS have remained constant at 20 cents. EPS estimates for 2025 have increased from 48 cents to 50 cents, during the same period. Year to date, shares of FOLD have lost 27.3%.
Amicus&#39; earnings beat estimates in three of the four trailing four quarters, missing the mark once, with the average surprise being 23.96%.
<a href="https://www.zacks.com/stock/news/2351620/mgtx-stock-up-on-upbeat-efficacy-data-from-parkinson-s-disease-study?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2351620">To read this article on Zacks.com click here.</a>

Regulations

MGTX

MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study

Piper Sandler has initiated coverage on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>),&nbsp;an integrated specialty pharmaceutical firm that develops and markets <a target="_blank" href="https://www.benzinga.com/quote/ANIP" rel="noreferrer noopener">branded and generic medicines</a>.
The analyst notes that ANI&#8217;s business model has significantly transformed, shifting from a primary emphasis on generics to a new focus on integrating high-margin brand assets aimed at rare diseases. Cortrophin Gel (adrenocorticotropic hormone (ACTH)), the company&#8217;s lead asset, has been the centerpiece of that evolution.
Cortrophin gel sales more than doubled to $49.2 million in the second quarter of 2024, driven primarily by increased volume. The company raised the fiscal year 2024 Cortrophin gel outlook from $170 million-$180 million <a href="https://www.benzinga.com/pressreleases/24/08/g40182933/ani-pharmaceuticals-reports-second-quarter-2024-financial-results-and-raises-2024-guidance" target="_blank" rel="noreferrer noopener">to $185 million-$195 million</a>.
The FDA approved Cortrophin Gel in 2021, which covers several autoimmune diseases. At that time, there was only one other ACTH player, Mallinckrodt Plc&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MNKTQ#OTC">MNKTQ</a>) Acthar Gel. The company and the drug have been associated with payer challenges, negative attention associated with the Medicaid rebate-related litigation and eventual settlement, and pandemic-associated disruption.
When ANI launched in the market, it identified significant promotion sensitivity linked to its relatively high-priced product, typically used after various more affordable immunomodulatory alternatives.
To address this, ANI developed a commercial framework concentrating on essential specialty areas, patient support systems, and market access.
Piper initiated with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/ANIP/analyst-ratings" rel="noreferrer noopener">price target of $68</a>.
Earlier this year, ANI Pharmaceuticals acquired Alimera Sciences for $5.50 per share in cash and one non-tradable contingent value right (CVR) of up to $0.50 per share upon achieving certain net revenue targets <a href="https://www.benzinga.com/general/biotech/24/06/39460281/generics-player-ani-pharmaceuticals-strengthens-rare-disease-segment-with-380m-alimera-sciences-d" target="_blank" rel="noreferrer noopener">in 2026 and 2027</a>.
With the acquisition, ANI gained Iluvien and Yutiq, both intravitreal implantable forms of the corticosteroid fluocinolone for diabetic macular edema and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40877461/ani-pharmaceuticals-inc-completes-acquisition-of-alimera-sciences" rel="noreferrer noopener">non-infectious uveitis</a>.
The transaction made sense, the analyst writes, especially since ANI had already established commercial infrastructure aimed at ophthalmologists to promote Cortrophin Gel, which is indicated for various ophthalmic conditions.
By incorporating Alimera&#8217;s current sales representatives, ANI can reach a broader pool of potential prescribers for Cortrophin Gel, thanks to the overlap with prescribers of Iluvien/Yutiq.
&#8220;ANI is well-positioned to de-lever considerably from the Alimera transaction in the next 12-18 months,&#8221; the analyst writes.
Price Action: ANIP stock is up 3.99% at $57.30 at last check Friday.
Photo: Illustration of Phrama lab worker created with MidJourney.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41295130/a-o-smith-slashes-fy24-guidance-as-china-woes-and-weak-water-heater-sales-drag-q3-performance" target="_blank" rel="noreferrer noopener">A.O. Smith Slashes FY24 Guidance As China Woes And Weak Water Heater Sales Drag Q3 Performance</a>.</li>
</ul>

Analyst Color

Equities

Health Care

Price Target

Initiation

Movers

MNKTQ

ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for ANI Pharmaceuticals, revealing an average target of $79.8, a high estimate of $94.00, and a low estimate of $60.00. Highlighting a 8.54% decrease, the current average has fallen from the previous average price target of $87.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1728648105_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of ANI Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Elliot Wilbur</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$83.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ANI Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for ANI Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into ANI Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind ANI Pharmaceuticals</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>Key Indicators: ANI Pharmaceuticals's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining ANI Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.44% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: ANI Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -1.95%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ANI Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.59%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ANI Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of -0.29%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: ANI Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.63.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights

Piper Sandler analyst David Amsellem initiates coverage on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Overweight rating and announces Price Target of $68.

Piper Sandler Initiates Coverage On ANI Pharmaceuticals with Overweight Rating, Announces Price Target of $68

AstraZeneca (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia.
The latest agreement is likely to strengthen AstraZeneca&#39;s cardiovascular pipeline, which is being studied for treating various cardiovascular diseases.
Year to date, shares of AstraZeneca have rallied 14.1% compared with the industry&#39;s rise of 18.5%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fa/80674.jpg?v=23295027" />
Image Source: Zacks Investment Research
<h2>More on AZN&#39;s Latest Agreement</h2>
Per the deal, AZN will make an upfront payment of $100 million to CSPC. The company is also entitled to pay up to $1.92 billion for further development and commercialization milestones plus tiered royalties to CSPC.
Per the latest agreement with CSPC, AstraZeneca will gain access to the latter&#39;s pre-clinical candidate, YS2302018, an oral Lp(a) disruptor, and develop the same for various cardiovascular diseases. The company will develop YS2302018 alone or in combination studies, including with the oral small molecule PCSK9 inhibitor, AZD0780.
Discovered by CSPC, YS2302018 has been shown to effectively prevent the formation of Lp(a), a form of low-density lipoprotein&nbsp;that plays a key role in transporting cholesterol in the bloodstream.
Per the company, the addition of YS2302018 to AZN&#39;s cardiovascular pipeline might help patients to more effectively manage their dyslipidaemia and cardiometabolic diseases.
<h2>AZN&#39;s Airsupra Meet Goal in BATURA Study</h2>
In a separate press release, AstraZeneca announced positive data from the phase IIIb BATURA study, which evaluated its pressurized metered-dose inhaler (pMDI), Airsupra (albuterol/budesonide).
Data from the study showed that treatment with Airsupra led to a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms versus as-needed albuterol in patients with intermittent or mild persistent asthma. This was the primary endpoint of the BATURA study.
Airsupra is approved for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and above in the United States. It is the first and only anti-inflammatory rescue medication for the given condition.
<h2>AZN&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
AstraZeneca currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), ADMA Biologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>), each sporting a Zacks Rank #1 (Strong Buy) at present. In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 1.3%.
ANIP&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for ADMA Biologics&#39; 2024 earnings per share have increased from 35 cents to 49 cents. Earnings per share estimates for 2025 have improved from 53 cents to 64 cents. Year to date, shares of ADMA have surged 346.5%.
ADMA&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 105.63%.
In the past 60 days, estimates for Alnylam&#39;s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 27 cents. Year to date, shares of ALNY have rallied 39.4%.
ALNY&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
<a href="https://www.zacks.com/stock/news/2347767/astrazeneca-inks-agreement-to-boost-cardiovascular-pipeline?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347767">To read this article on Zacks.com click here.</a>

Events

ADMA

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

Ionis Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ions#NASDAQ">IONS</a>) announced that the FDA has granted a Fast Track designation to its investigational RNA-targeted therapy zilganersen for treating Alexander disease (AxD), an ultra-rare neurological disorder.
The Fast Track designation from the FDA facilitates rapid development and expedites the review of drug candidates to treat serious conditions for which clinical data demonstrate the potential to address unmet medical needs. The goal is to make these treatments rapidly available to patients in need.
AxD is a rare neurological disease that affects a type of cell in the brain called astrocytes, which has multiple roles in the brain to support neurons and oligodendrocytes. People living with this condition experience cognitive dysfunction and progressive neurologic deterioration, including swallowing and the ability to control muscles for large movements. Per Ionis, zilganersen is the first investigational medicine in clinical development for treating AxD. There are currently no approved therapies for AxD patients.
The FDA had previously granted Orphan Drug designation and Rare Pediatric Disease designation to zilganersen for treating AxD.
Shares of Ionis have declined 22.8% so far this year compared with the industry&#39;s 1.3% fall.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a1/79966.jpg?v=1130269560" />
Image Source: Zacks Investment Research
<h2>Recent Updates on IONS&#39; Zilganersen</h2>
Zilganersen is currently being evaluated in late-stage studies for treating adults and children living with AxD.
The company completed full patient enrollment in a pivotal phase III study on zilganersen for treating AxD in July. Top-line data from the same is expected in the second half of 2025.
The primary endpoint of the study is to check the percent change from baseline in gait speed as assessed by the 10-Meter Walk Test (10MWT) at the end of the 60-week treatment period.
Zilganersen is one of Ionis&#39; wholly-owned pipeline candidates. The company intends to launch it independently in the United States.
<h2>IONS&#39; Promising Wholly Owned Pipeline</h2>
Ionis has collaborations with leading drugmakers/biotech companies that provide it with funds in the form of license fees, upfront payments and milestone payments to invest in its internal pipeline development.
Besides zilganersen, some of its wholly-owned candidates include olezarsen for familial chylomicronemia syndrome&nbsp;and severe hypertriglyceridemia, donidalorsen for hereditary angioedema and ulefnersen for amyotrophic lateral sclerosis, which is in phase III study.
In April 2024, Ionis filed a new drug application (NDA) with the FDA seeking approval for olezarsen in the FCS indication. A decision from the regulatory body is due on Dec. 19, 2024.
If approved, olezarsen will be Ionis&#39; first medicine to be launched independently.
Also, Ionis is making preparations to file an NDA for donidalorsen with the FDA later in 2024. The company expects donidalorsen to be its second independent commercial launch upon potential approval.
<h2>IONS&#39; Zacks Rank &amp; Stocks to Consider</h2>
Ionis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 7.8%.
ANIP&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.91 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 46.3%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from 46 cents to 28 cents. Loss per share estimates for 2025 have narrowed from $1.67 to $1.14. Year to date, shares of FULC have plunged 46.7%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2344661/ions-rare-neurology-disorder-candidate-gets-fda-s-fast-track-tag?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2344661">To read this article on Zacks.com click here.</a>

Penny Stocks

FULC

IONS

KRYS

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

NI&#39;s Ketoconazole Shampoo,&nbsp;2%&nbsp;is the generic version of the reference listed drug (RLD) Nizoral.
U.S. annual sales for Ketoconazole Shampoo,&nbsp;2%&nbsp;total approximately&nbsp;$69.2 million, based on July 2024 moving annual total (MAT) IQVIA data. 
&nbsp;

ANI Pharmaceuticals Reports FDA Approval And Commercialization Of Ketoconazole Shampoo, 2%

Shares of Biohaven Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bhvn#NYSE">BHVN</a>) were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease.
Currently, there are no FDA-approved therapy for the given indication.
The study showed the efficacy of troriluzole on the mean change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) following three years of treatment.
Year to date, shares of Biohaven have gained 7.4% with no change for the industry.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ee/78970.jpg?v=729085404" />
Image Source: Zacks Investment Research
<h2>BHVN&#39;s Pivotal BHV4157-206-RWE Study Data</h2>
The study met the primary endpoint on the change from baseline in the f-SARA at three years in all study population genotypes following treatment with troriluzole (200 mg) in SCA patients.
Also, treatment with troriluzole led to statistically significant improvements in the f-SARA at years one and two. Data collected from multiple analyses showed a robust and clinically meaningful slowing of disease progression in SCA patients.
Importantly, treatment with troriluzole slowed disease progression by 50% to 70%, representing a 1.5-2.2 years delay in disease progression over three years compared to untreated patients.
Treatment with troriluzole demonstrated statistically significant superiority on nine consecutive, prespecified primary and secondary endpoints of the study.
Per management, troriluzole is the first treatment to show a delay in disease progression for SCA patients.
<h2>BHVN&#39;s Upcoming Plans for Troriluzole</h2>
Based on the positive data from the BHV4157-206-RWE study, along with previous safety and efficacy data, BHVN plans to submit a new drug application (NDA) for troriluzole in SCA with the FDA in the fourth quarter of 2024.
If approved, the company plans to launch troriluzole in the United States in 2025.
The FDA has granted Fast-Track and orphan drug designation to troriluzole for treating SCA. The European Medicines Agency has also granted orphan drug designation to troriluzole for treating SCA.
As a result of the orphan drug and fast-track designations granted by the FDA, the NDA for troriluzole is eligible for a priority review.
Troriluzole is also being evaluated in two late-stage studies for treating obsessive-compulsive disorder (OCD). Interim analysis of the second phase III OCD study is expected later in 2024, while top-line data from the first phase III OCD study is anticipated in the first half of 2025.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Biohaven currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.49 to $4.82. Earnings per share estimates for 2025 have improved from $5.51 to $5.93. Year to date, shares of ANIP have gained 9%.
ANIP&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $2.09 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 45.3%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, with the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.33 to 28 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 52.6%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2340700/bhvn-stock-up-as-rare-neurological-disease-study-meets-primary-goal?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2340700">To read this article on Zacks.com click here.</a>

BHVN

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

Raymond James analyst Elliot Wilbur maintains ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Outperform and raises the price target from $81 to $83.

Raymond James Maintains Outperform on ANI Pharmaceuticals, Raises Price Target to $83

ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $85.5, a high estimate of $94.00, and a low estimate of $60.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.66%. 
<img src="https://www.benzinga.com/files/images/story/2024/1726574513_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of ANI Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ANI Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ANI Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of ANI Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ANI Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ANI Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into ANI Pharmaceuticals's Background</h2>
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
<h3>ANI Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, ANI Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 18.44% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: ANI Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -1.95%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ANI Pharmaceuticals's ROE excels beyond industry benchmarks, reaching -0.59%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching -0.29%. This signifies efficient management of assets and strong financial health.
Debt Management: ANI Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.63, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals

HC Wainwright &amp; Co. analyst Oren Livnat reiterates ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Buy and maintains $94 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on ANI Pharmaceuticals, Maintains $94 Price Target

Ani Pharmaceuticals Launches Promethazine Hydrochloride And Dextromethorphan Hydrobromide Oral Solution

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02a43eaaa00018d939e/edward-white">HC Wainwright &amp; Co. analyst Edward White</a> downgraded the rating for Adicet Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Buy to Neutral. Adicet Bio shares fell 3.4% to close at $1.43 on Tuesday. <a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">See how other analysts </a><a href="https://www.benzinga.com/quote/ACET/analyst-ratings">view </a><a href="https://www.benzinga.com/quote/DACETPZ/analyst-ratings">this stock</a>.</li>
<li>B of A Securities analyst Graham Perry downgraded Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Neutral and lowered the price target from $135 to $130. Novartis shares fell 0.2% to close at $116.99 on Tuesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/topic/david-amsellem">Piper Sandler analyst David Amsellem</a> downgraded the rating for Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) from Overweight to Neutral and cut the price target from $41 to $36. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. <a href="https://www.benzinga.com/quote/SUPN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Gregory Fraser downgraded ANI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) from Buy to Hold and slashed the price target from $80 to $60. ANI Pharmaceuticals shares fell 5.1% to close at $55.48 on Tuesday. <a href="https://www.benzinga.com/quote/ANIP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NVS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="537" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png" alt="" class="wp-image-542353" style="width:625px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-1024x537.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11091806/image-88.png 1292w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:<a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40792510/jim-cramer-says-aes-is-very-inexpensive-recommends-buying-this-industrial-stock">Jim Cramer Says AES Is &#8216;Very Inexpensive&#8217;, Recommends Buying This Industrial Stock</a></li>
</ul>

Downgrades

ACET

RLAY

SUPN

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday

ALIM

ANI Pharmaceuticals And Alimera Sciences Announced That They Have Scheduled The Closing Of Their Transaction Pursuant To The Companies' Previously Announced Merger Agreement Before The Market Opens On Monday, September 16, 2024

Truist Securities analyst Gregory Fraser downgrades ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) from Buy to Hold and lowers the price target from $80 to $60.

Truist Securities Downgrades ANI Pharmaceuticals to Hold, Lowers Price Target to $60

ANI Pharmaceuticals Updates On Alimera Sciences Acquisition, States Discussions Regarding Closing Conditions Are Ongoing But Expected To Be Resolved Promptly

Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations
Alimera Shareholders Approved Merger Agreement on September 4, Clearing Last Requirement for Closing

Legal

Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals To Force It To Fulfill Its Contractual Obligation For Merger Agreement

WIIM

ANI Pharmaceuticals shares are trading lower after the company announced intent for a $250 million private offering of convertible senior notes.

Analyst Les Sulewski of Truist Financial maintained a Hold rating on ANI Pharmaceuticals (ANIP – Research Report), with a price target of $60.00. L...

Hold Rating on ANI Pharmaceuticals Amid Acquisition Concerns and Growth Uncertainty

ANI Pharmaceuticals, Alimera Sciences deal set to close Monday

Alimera Sciences: Deal Closing After All, CVR Still Attractive

ANI Pharmaceuticals falls amid Truist downgrade on delayed Alimera deal close

Deals this week: Qualcomm, Squarespace, Adnoc, General Mills and more

ANI Pharmaceuticals completes purchase of Alimera Sciences

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), with a price ...

ANI Pharmaceuticals' Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target Price

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

ANI Pharmaceuticals (ANIP) has received a new Buy rating, initiated by Piper Sandler analyst, David Amsellem. David Amsellem has given his Buy rati...

Buy Rating Affirmed: ANI Pharmaceuticals' Transition to High-Margin Rare Disease Brands Fuels Growth Potential

ANI earns bullish view at Piper Sandler on portfolio mix

BSRUF

CELTF

CRZBF

CRZBY

FYBR

INST

INTC

MEOH

NPSCY

QCOM

SQSP

SVNDY

UNCFF

UNCRY

UUUU

VSTO

Financing

Press Releases

ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers' Option to Purchase Additional Notes

ALIMERA SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alimera Sciences, Inc. - ALIM

Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement

ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences

ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution

ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%

Comments

ANI Pharmaceuticals

Vendite allo scoperto

ANI Pharmaceuticals (NASDAQ:ANIP) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO